ModelEdge

Arca Biopharma Inc.
ABIO
Filing TypeS-3
Filing Date8/20/2026
Updated8/21/26, 2:18 PM

Filing

S-3
Earnings Release

Exhibits

S-3Registration Statement for Securities Offered under a Shelf Registration
EX-1.3AMENDMENT NO. 1 TO THE SALES AGREEMENT BETWEEN ORUKA THERAPEUTICS, INC. AND TD SECURITIES (USA) LLC, DATED AUGUST 21, 2026
EX-5.1OPINION OF DAVIS POLK & WARDWELL LLP RELATING TO THE BASE PROSPECTUS
EX-5.2OPINION OF DAVIS POLK & WARDWELL LLP RELATING TO THE SALES AGREEMENT PROSPECTUS
EX-23.1CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
EX-FILING FEESFILING FEE TABLE
GRAPHICGraphic
GRAPHICGraphic
GRAPHICGraphic
GRAPHICGraphic
GRAPHICGraphic